New York doctors who are beginning tests of an experimental vaccine for open-heart surgery patients say they hope the shot will keep MRSA at bay. The aim of the vaccine is to prevent bloodstream and surgical wound infections, and Merck & Co. is testing it in 84 countries. The clinical trial is expected to run three to six months.
Trending:
Experimental vaccine seen as hope against MRSA